Stereoselective functionalization of pyrrolidinone moiety towards the synthesis of salinosporamide A

Julien Barbion, Geoffroy Sorin, Mohamed Selkti, Esther Kellenberger, Rachid Baati, Stefano Santoro, Fahmi Himo, Ange Pancrazi, Marie-Isabelle Lannou, Janick Ardisson

► To cite this version:

Julien Barbion, Geoffroy Sorin, Mohamed Selkti, Esther Kellenberger, Rachid Baati, et al.. Stereoselective functionalization of pyrrolidinone moiety towards the synthesis of salinosporamide A. *Tetrahedron*, 2012, 68 (32), pp.6504-6512. 10.1016/j.tet.2012.05.103 . hal-02370605

HAL Id: hal-02370605

<https://hal.science/hal-02370605>

Submitted on 14 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Stereoselective functionalization of pyrrolidinone moiety towards the synthesis of salinosporamide A

Julien Barbion^a, Geoffroy Sorin^a, Mohamed Selkti^b, Esther Kellenberger^c, Rachid Baati^d, Stefano Santoro^e, Fahmi Himo^e, Ange Pancrazi^a, Marie-Isabelle Lannou^{a,*}, Janick Ardisson^{a,*}

^a Faculté de Pharmacie, CNRS UMR 8638, Université Paris Descartes, 4 avenue de l'Observatoire, 75270 Paris Cedex, France

^b Faculté de Pharmacie, CNRS UMR 8015, Université Paris Descartes, 4 avenue de l'Observatoire, 75270 Paris Cedex, France

^c Faculté de Pharmacie, CNRS UMR 7200, Université de Strasbourg, 74 route du Rhin, 67400 Illkirch, France

^d Faculté de Pharmacie, Université de Strasbourg, CNRS-UMR 7199, Laboratoire des Systèmes Chimiques Fonctionnels, 74 route du Rhin, 67400 Illkirch, BP 60024, France

^e Department of Organic Chemistry, Arrhenius Laboratory, Stockholm University, S-106 91 Stockholm, Sweden

ABSTRACT

An important feature of the synthesis of salinosporamide A, a potent proteasome inhibitor, is the establishment of the quaternary stereocenter at C3. A new route has been developed based on the methylation of a functionalized pyrrolidinone. Direct methylation reaction led to the unwanted diastereomer; however, by means of a Corey–Chaykovsky reaction followed by LiAlH₄ epoxide opening, the desired alcohol was obtained. The pyrrolidinone was elaborated through a key allylation reaction between a tertiary allyltitanium reagent and an aldehyde bearing a spiroketal moiety in α -position.

Keywords:

Salinosporamide

Hoppe allylation

Pyrrolidinone

Methylation reaction

Corey–Chaykovsky reaction

1. Introduction

Recently, sea-water requiring microorganisms have begun to emerge as a new and sustainable source for novel chemical entities. For example, one particular rich source is the actinomycete bacteria of the genus *Salinospora*, which produces a very high potent and selective proteasome inhibitor, salinosporamide A **1**. This marine product, discovered by Fenical, has been shown to possess in vitro cytotoxicity against many cancer cell lines with IC₅₀ values less than 10 nM. Consequently, salinosporamide A **1** is currently in clinical trials for the treatment of cancer.¹

Structurally, salinosporamide A **1** possesses a highly functionalized γ -lactam- β -lactone framework containing two contiguous tetrasubstituted carbon centres (Fig. 1).¹

The global structural complexity of salinosporamide A **1** combined to its impressive biological profile makes it an attractive

Fig. 1. Structure of salinosporamide A **1**.

target for research studies in different fields, including total synthesis, structure–activity, biosynthetic engineering and crystallography with the 20S proteasome.

One main feature of the salinosporamide A synthesis is the establishment of the quaternary centre at C3. Although different synthetic pathways have been proposed,^{2–5} the creation of the C3 centre was generally simultaneously produced with the pyrrolidine core by forming either C2–C3^{3a,c,f,4b,e} or C3–C4^{3d,g–i,k–n} bond, respectively (Schemes 1 and 2).

Key steps involved the Kulinkovitch, Baylis–Hillman or more frequently intramolecular aldol reaction.

Less often, the set-up of this centre was achieved directly on the functionalized pyrrolidine core through cyclization or dihydroxylation reaction (Scheme 3).^{3b,e,4a,f}

* Corresponding authors. Tel.: +33 (0) 1 53 73 97 54; fax: +33 (0) 1 43 29 14 03 (M.-I.L.); tel.: +33 (0) 1 53 73 97 54; fax: +33 (0) 1 43 29 14 (J.A.); e-mail addresses: marie-isabelle.lannou@parisdescartes.fr (M.-I. Lannou), janick.ardisson@parisdescartes.fr (J. Ardisson).

Scheme 1. Creation of the C3 centre by forming C2–C3 bond.

Scheme 2. Creation of the C3 centre by forming C3–C4 bond.

2. Results and discussion

For the synthesis of salinosporamide **1**, our strategy involved the control of centre at C3 (salinosporamide carbon numbering) by stereoselective methylation of the pyrrolidinone **6** to provide alcohol **7** (Scheme 4). The preparation of this pyrrolidinone **6** depended on the elaboration of the homoallylic alcohol **5** through an allylation reaction.

Aldehyde allylation reaction by means of in situ generated chiral allyltitanium reagents, to yield *anti* homoallylic carbamates with excellent selectivity, has been initially developed by Hoppe and widely used in total synthesis by our group.^{6,7} In the design of a synthesis of salinosporamide A **1**, we focused our attention on the

Scheme 3. Creation of the C3 centre directly on the functionalized pyrrolidine core.

Scheme 4. Retrosynthetic strategy to salinosporamide A **1**.

allylation of aldehyde **3** including a spiroketal moiety in α -position by tertiary allyltitanium (*R*)-**4**. Aldehyde **3** arose from 2-amino-2-(hydroxymethyl)propane-1,3-diol (Tris) **2**. Synthesis of allyltitanium (*R*)-**4** could be achieved through (+)-DIPT Sharpless epoxidation reaction of allylic alcohol ($\pm$)-**8** in a kinetic resolution strategy followed by carbamoylation reaction and treatment of the resulting allyl diisopropylcarbamate (*S*)-**9** with *n*-BuLi/(–)-TMEDA and tetra-(isopropoxy)titanium, as described by us in previous publications.^{7h,i}

We examined this approach in a racemic version. Allylcarbamate ($\pm$)-**11** was synthesized from homopropargylic alcohol in four steps: protection of the hydroxyl function, homologation, reduction of the triple bond and then carbamoylation of the resulting allylic alcohol ($\pm$)-**10**.

In the meantime, 2-amino-2-(hydroxymethyl)propane-1,3-diol (Tris) **2** was successively subjected to *tert*-butoxycarbonylation and acetalization to deliver alcohol **12** in 90% yield. Subsequent Swern oxidation afforded the corresponding aldehyde **13** (Scheme 5).⁸

Scheme 5. Synthesis of the *anti* homoallylic alcohol (±)-15. (a) Imidazole, TPSCl, THF, rt, 24 h; (b) *n*-BuLi in hexanes, THF, -78°C , 1 h then CH_3CHO , $-78^{\circ}\text{C} \rightarrow \text{rt}$, 1 h; (c) Red-Al[®] in toluene, THF, 0°C , 4 h, 94% over three steps; (d) KH, THF, $0^{\circ}\text{C} \rightarrow \text{rt}$, 20 min, then diisopropylcarbamoyl chloride, THF, rt, 0.5 h, 94%; (e) Boc_2O , *t*-BuOH/MeOH (1:1), rt, 1 h; (f) 2,2-dimethoxypropane, PTSA, CH_2Cl_2 , rt, 0.5 h, 90% over two steps; (g) oxalyl chloride, DMSO, CH_2Cl_2 , rt, 0.5 h, then **12**, CH_2Cl_2 , rt, 0.5 h, 97%; (h) (±)-11, TMEDA, *n*-BuLi in hexanes, Et_2O , -78°C , 1 h, $\text{Ti}(\text{O}i\text{-Pr})_4$, then **13**, THF, -78°C , 2 h, 76%, dr >95:5. Red-Al[®]=Sodium bis(2-methoxyethoxy)aluminium hydride, TMEDA=*N,N,N',N'*-Tetra-methyl-ethane-1,2-diamine.

Hoppe allylation of the sterically hindered aldehyde **13** by tertiary allyltitanium (±)-14 proceeded in high yield and total control of diastereoselectivity to provide *anti* homoallylic alcohol (±)-15, having the framework of salinosporamide A.⁹ Allyltitanium (±)-14 was readily prepared in situ from secondary allyl diisopropylcarbamate (±)-11, through *n*-BuLi/TMEDA deprotonation and tetra-(isopropoxy)titanium transmetallation.

Exposure of vinylcarbamate (±)-15 to ozone and subsequent treatment of the resulting hemiaminal with NaBH_3CN produced 3-hydroxypyrrolidine (±)-16, which was further subjected to Dess–Martin oxidation to afford pyrrolidinone (±)-17 (Scheme 6).

Scheme 6. Synthesis of the pyrrolidinone (±)-17. (a) O_3 , CH_2Cl_2 , -78°C , 0.5 h, Me_2S , $-78^{\circ}\text{C} \rightarrow \text{rt}$, overnight; (b) NaBH_3CN , MeOH/AcOH (1:1), rt, 0.5 h, 50% over two steps; (c) Dess–Martin periodinane, CH_2Cl_2 , rt, 1 h, 91%.

At this stage, control of the C3 centre was envisioned through stereoselective methylation of pyrrolidinone (±)-17 to access the tertiary alcohol (±)-18 (Scheme 6). Very few publications have

dealt with the controlled methylation of pyrrolidin-3-ones bearing an alkyl chain at C2 (salinosporamide carbon numbering). Therefore, based on literature reports, the diastereoselectivity of the alkylation of such functionalized pyrrolidinones could not be clearly predicted.¹⁰

For this reason, a three-dimensional structure of the pyrrolidinone (±)-17 was modelled using the Sybyl method.¹¹ Although there is no strong steric hindrance of the C3 carbon by the vicinal spiroketal group and alkyl chain, pure geometric considerations would support a preferential addition of the methylating agent on the opposite side to the alkyl chain at C2, hypothetically leading to (±)-18.

To validate this hypothesis, various methylating reagents were reacted with (±)-17. Among them, methylmagnesium bromide trimethylaluminium and dimethylzinc were inefficient in producing (±)-18, resulting in the recovery of the starting material or its degradation. In contrast, the use of MeLi or MeLi/CeCl₃,¹² delivered the unwanted tertiary alcohol derivative (±)-19 as a single isomer in a satisfactory yield (along with starting material (±)-17) (Scheme 7).

Scheme 7. Synthesis of the tertiary alcohol (±)-19 through direct methylation. (a) MeLi, THF, -78°C , 4 h, 41%, dr 100:0; (b) dried CeCl_3 (from $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$), MeLi, THF, -78°C , 2 h, 65%, dr >95:5.

The configuration of the C3 centre was established by NOESY NMR experiments of pyrrolidine (±)-19 and its corresponding γ -lactam (±)-20 (obtained from (±)-19 through $\text{RuCl}_3 \cdot \text{H}_2\text{O}/\text{NaIO}_4$ oxidation).¹³ The structure was unambiguously confirmed by X-ray crystallography of the *O*-*p*-NO₂Bz ester (±)-21 (Scheme 8).

Contrary to the predictions, the nucleophilic attack of the methyl group occurred from the same side as the C2 chain of ketone (±)-17, resulting in the *trans*-disposition of the hydroxyl group and the chain.

To gain a better understanding of the reaction mechanism, density functional theory (DFT) calculations were performed on the methylation step. To model the reaction, a slightly modified system was used in order to reduce the number of rotamers that were needed to be investigated. Hence, the TPS group was substituted by a methyl, as well as the *tert*-butyl group of Boc ($\text{R}^1=\text{R}=\text{Me}$). Since the reaction was under kinetic control, the selectivity derives from the energy difference between transition states. Therefore, the two transition states leading to the two diastereomers have been optimized (see Fig. 2 for optimized structures and energies).

The calculations indeed show that the TS leading to the *trans*-product has a lower energy than the one leading to the *cis*-product (calculated difference is 1.1 kcal/mol). This is an underestimation, due to the model used in the calculations, but it is still excellent considering the approximations made in the calculations. The energy difference probably arose from the different conformations of the five-membered ring in its transition states. While in the *trans*-TS, the ring assumes a preferred envelope-conformation, in the *cis*-TS it resembles more a half-chair conformation. Furthermore, in the *trans*-TS, the bulky side chain is in an equatorial position, while it is forced to assume a 'less-equatorial' position in the *cis*-TS, due to the bending of the carbonyl towards the nucleophile.

These observations can explain the experimental observed findings.

The methylation reaction was examined with different starting materials using the same preceding experimental conditions (MeLi, THF/MeLi, CeCl_3 , THF, -78°C). Among the methylation tested: (i) pyrrolidinones without spiroketal moiety at C4,¹⁴ (ii) linear ketones¹⁵ and (iii) lactam,¹⁶ none of them gave satisfactory results. We also investigated the stereocontrolled facial addition of the methyl group in presence of optically active ligands and dimethylzinc; however, all attempts failed to give the expected product.¹⁷

($\pm$)-**18** was obtained as a single isomer (Scheme 9). The relative stereochemistry of ($\pm$)-**18** was determined unambiguously by 2D-NOESY experiments and compared to those obtained for ($\pm$)-**19**. It is important to note that starting from the same substrate ($\pm$)-**17**, different reagents (MeLi/CeCl₃ or sulfoxonium ylide as nucleophile) led to opposite selectivity. Unfortunately, to date, no valuable hypothesis can be proposed to explain this reversal of selectivity. Kinetic or thermodynamic control could be suggested.

Noteworthy, pyrrolidinol ($\pm$)-**18** is structurally very close to the advanced intermediate ($\pm$)-**22** described by Pattenden during the course to total synthesis of salinosporamide **1** (Scheme 10).^{31,m}

Towards the synthesis of the salinosporamide pyrrolidine core, two key-steps have been studied. At first, a novel high-yielding allylation reaction between a tertiary allyltitanium reagent and an aldehyde bearing a spiroketal moiety in α -position was described. This reaction readily offered access to the entire core of salinosporamide A. The second step was the control of the diastereoselectivity of the quaternary stereocenter at C3. We expected that the methylation of the corresponding substituted pyrrolidinone ($\pm$)-**17** would deliver the right diastereomer, assuming that methylating agents would add from the less hindered direction. Surprisingly, using MeLi or MeLi/CeCl₃ reagents under kinetic control, the undesired tertiary alcohol ($\pm$)-**19** was isolated as a single isomer. DFT calculations, performed on this methylation step, explained this result and improved our understanding of the transition states. Finally, an alternative sequential Corey–Chaykovsky reaction/LiAlH₄ epoxide opening produced the expected alcohol ($\pm$)-**18**. This result obviously established that the Corey–Chaykovsky reaction, with sulfoxonium ylide as nucleophile, occurred with an opposite stereoselectivity.

Importantly, the potential and applicability of this approach for the synthesis of salinosporamide A **1** have been demonstrated with the synthesis of the pyrrolidinol ($\pm$)-**18**.

4. Experimental section

4.1. General

All commercially available reagents and solvents (Fluka, Aldrich, Acros, Fisher) were used without further purification. For reactions requiring anhydrous conditions, dry solvents were bought (Fluka, Aldrich) or freshly distilled prior to use (THF and Et₂O over sodium/benzophenone system, DCM and DMSO over calcium hydride and MeOH and EtOH over magnesium). Unless otherwise noted, experiments were carried out under argon. Reactions were monitored by TLC (Merck silica gel 60 F₂₅₄ plates) with detection by use of UV light (254 nm & 366 nm) or a phosphomolybdic acid solution in EtOH (5%) followed by heating at 100–110 °C. Purifications were performed by flash chromatography on silica gel (Merck silica gel 60, 40–63 μ m). ¹H NMR spectra were recorded with Bruker AVANCE 300 and AVANCE 400 spectrometers at, respectively 300 and 400 MHz. Chemical shifts are given in parts per million relative to the residual ¹H solvent signal (CDCl₃: δ =7.26 ppm) as the internal reference. ¹H NMR assignments were confirmed by 2D COSY spectra. The multiplicities given reflect apparent signal patterns. ¹³C NMR spectra were recorded with the same instruments as above at 100 MHz. Chemical shifts are given in ppm relative to the residual ¹³C solvent signal (CDCl₃: δ =77.0 ppm). ¹³C NMR assignments were confirmed by 2D HSQC spectra. Coupling constants (*J*) are given in hertz for all NMR spectroscopic data. Melting points were measured with a Büchi 510 apparatus and are uncorrected. IR spectra were recorded with a Perkin Elmer Spectrum 65 FT-IR spectrometer. Mass spectra were recorded with the following instruments: ESI-MS: Waters ZQ 2000 spectrometer and ESI-TOF-HRMS: Waters LCT Premier spectrometer. CCDC-857729 [($\pm$)-**19**] contain the supplementary crystallographic data. The data can be obtained free of charge from the Cambridge Crystallographic Data Centre TH through <http://www.ccdc.cam.ac.uk/>.

Computational details. All calculations were performed using the B3LYP functional¹⁹ as implemented in the Gaussian 03 software package.²⁰ Geometries were optimized with the 6-31G(d,p) basis set for all atoms, and characterized with frequency calculations. Final energies were obtained with the larger 6-311+G(2d,2p) basis set on all atoms and corrected for zero-point effects obtained from the frequency calculations. The effect of solvation in THF was calculated using the conductor-like polarizable continuum model (CPCM)²¹ with UAKS radii.

4.2. (E)-6-[(*tert*-Butyldiphenylsilyl)oxy]hex-3-en-2-ol ($\pm$)-**10**

Imidazole (3.47 g, 51.0 mmol), DMAP (186 mg, 1.5 mmol) and TPSCI (12 mL, 45.0 mmol) were successively added to a solution of 3-butyne-1-ol (2.21 g, 30.0 mmol) in THF (60 mL). The reaction mixture was stirred at room temperature for 24 h and then H₂O (90 mL) was added. The mixture was extracted with EtOAc. The organic layers were washed with brine, dried (MgSO₄), filtered and the solvent removed under reduced pressure. The residue was purified by chromatography on silica gel (cyclohexane/Et₂O 99:1 to 98:2) to give 11.07 g of 4-[(*tert*-butyldiphenylsilyl)oxy]but-1-yne as a colourless oil.

¹H NMR (400 MHz, CDCl₃): δ =7.60 (m, 4H), 7.33 (m, 6H), 3.71 (t, *J*=0.9 Hz, 2H), 2.38 (t, *J*=0.9 Hz, 2H), 1.88 (s, 1H), 0.98 (s, 9H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ =135.6, 133.5, 129.7, 127.7, 81.4, 69.3, 62.2, 26.7, 22.5, 19.2 ppm.

A solution of *n*-BuLi (1.6 M in hexanes, 21 mL, 33.7 mmol) was added to a solution of the previous product (30.0 mmol) in THF

(60 mL) at –78 °C. The reaction mixture was stirred at –78 °C for 1 h and then freshly distilled acetaldehyde (4.4 mL, 76.5 mmol) was added quickly. The reaction mixture was warmed up to room temperature and stirred for 1 h before HCl (1.0 M, 20 mL) was added. The mixture was extracted with Et₂O. The organic layers were washed subsequently with H₂O and brine, dried (MgSO₄), filtered and the solvent removed under reduced pressure. The residue was purified by chromatography on silica gel (cyclohexane/EtOAc 1:1) to give 13.47 g of 6-[(*tert*-butyldiphenylsilyl)oxy]hex-3-yn-2-ol as a yellow oil.

¹H NMR (400 MHz, CDCl₃): δ =7.60 (m, 4H), 7.33 (m, 6H), 4.40 (m, 1H), 3.69 (t, *J*=6.9 Hz, 2H), 2.40 (td, *J*=6.9/1.8 Hz, 2H), 1.64 (s, 1H), 1.32 (d, *J*=6.4 Hz, 3H), 0.98 (s, 9H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ =135.5, 133.5, 129.7, 127.6, 83.1, 81.6, 62.3, 58.8, 26.7, 24.5, 22.8, 19.2 ppm.

A solution of Red-Al® (3.5 M in toluene, 14 mL, 49.0 mmol) was added to a solution of the previous product (30.0 mmol) in THF (60 mL) at 0 °C. The reaction mixture was stirred at this temperature for 4 h and then quenched by a slow addition of HCl (1.0 M, 50 mL). The reaction mixture was warmed up to room temperature and then extracted with Et₂O. The organic layers were washed with NaHCO₃ and brine, dried (MgSO₄), filtered and the solvent removed under reduced pressure. The residue was purified by chromatography on silica gel (cyclohexane/Et₂O 1:1) to give 10.24 g (94% yield over three steps) of required product ($\pm$)-**10** as a colourless oil.

¹H NMR (400 MHz, CDCl₃): δ =7.59 (m, 4H), 7.33 (m, 6H), 5.51 (m, 2H), 4.16 (m, 1H), 3.63 (t, *J*=6.9 Hz, 2H), 2.20 (td, *J*=6.9/6.4 Hz, 2H), 1.30 (s, 1H), 1.16 (d, *J*=6.4 Hz, 3H), 0.98 (s, 9H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ =136.1, 135.6, 133.9, 129.6, 127.6, 127.4, 68.9, 63.4, 35.5, 26.8, 23.2, 19.2 ppm.

4.3. (E)-6-[(*tert*-Butyldiphenylsilyl)oxy]hex-3-en-2-yl diisopropylcarbamate ($\pm$)-**11**

A solution of the precedent alkene ($\pm$)-**10** (9.52 g, 26.8 mmol) in THF (45 mL) was added to a solution of KH (30% in mineral oil, 5.11 g, 37.6 mmol), previously washed with cyclohexane, in THF (40 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 5 min and for 20 additional minutes at room temperature. Then, a solution of diisopropylcarbamoyl chloride (5.0 g, 29.5 mmol) in THF (20 mL) was added and the mixture was stirred for 30 min at room temperature. The reaction mixture was neutralized by addition of HCl (1.0 M, 35 mL) at 0 °C, warmed up to room temperature and then extracted with Et₂O. The organic layers were washed with brine, dried (Na₂SO₄), filtered and the solvent removed under reduced pressure. The residue was purified by chromatography on silica gel (cyclohexane/Et₂O 9:1) to give 12.14 g (94% yield) of the required product ($\pm$)-**11** as a colourless oil.

¹H NMR (400 MHz, CDCl₃): δ =7.61 (m, 4H), 7.33 (m, 6H), 5.62 (td, *J*=15.6/6.9 Hz, 1H), 5.49 (dd, *J*=15.6/6.0 Hz, 1H), 5.20 (td, *J*=6.4/6.0 Hz, 1H), 4.03 (s large, 1H), 3.61 (t, *J*=6.9 Hz, 2H), 3.59 (s, 1H), 2.21 (td, *J*=6.9/6.9 Hz, 2H), 1.22 (d, *J*=6.4 Hz, 3H), 1.11 (d, *J*=6.9 Hz, 12H), 0.96 (s, 9H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ =155.1, 135.5, 133.9, 132.6, 129.5, 128.2, 127.6, 71.0, 63.4, 46.6, 45.6, 35.6, 26.8, 26.7, 20.7, 19.2 ppm. IR (thin film): ν =2931, 1687, 1473, 1428, 1368, 1286, 1215, 1107, 1045, 967, 925, 822, 770, 737 cm^{–1}. MS (40 eV, ES): *m/z* (%): 520 (5) [M+K]⁺, 504 (100) [M+Na]⁺, 102 (10). ESI-HRMS: calcd for C₂₉H₄₃NO₃Si [M+Na]⁺ 504.2910; found 504.2901.

4.4. *tert*-Butyl-5-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-5-ylcarbamate **12**

A solution of Boc₂O (7.0 mL, 32.5 mmol) in *t*-BuOH (12.5 mL) was added to a solution of trishydroxymethylaminomethane (Tris) **2** (3.0 g, 25.0 mmol) in a mixture *t*-BuOH/MeOH (1:1) (50 mL). The reaction mixture was stirred at room temperature for 24 h. The

solvent was removed under reduced pressure and the crude *tert*-butyl-1,3-dihydroxy-2-(hydroxymethyl)propan-2-ylcarbamate was isolated as a white powder.

¹H NMR (400 MHz, CDCl₃): δ=5.44 (s, 1H), 3.61 (d, *J*=5.9 Hz, 6H), 3.30 (t, *J*=5.9 Hz, 3H), 1.20 (s, 9H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ=157.0, 80.5, 63.9, 59.6, 28.3 ppm.

2,2-Dimethoxypropane (9.4 mL, 75.0 mmol) and PTSA (240 mg, 1.25 mmol) were added to a solution of the previous crude product (25.0 mmol in theory) in CH₂Cl₂ (125 mL). The reaction mixture was stirred at room temperature for 30 min and then neutralized with Et₃N (210 μL, 1.5 mmol). The solvent was removed under reduced pressure and the residue was purified by chromatography on silica gel (cyclohexane/EtOAc 1:1) to give 5.89 g (90% yield over two steps) of the required product **12** as a white powder.

¹H NMR (400 MHz, CDCl₃): δ=5.27 (broad s, 1H), 4.22 (s, 1H), 3.78 (m, 2H), 3.74 (m, 2H), 3.66 (d, *J*=6.9 Hz, 2H), 1.39 (s, 9H), 1.37 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ=156.4, 98.7, 80.5, 64.7, 64.4, 53.3, 28.3 ppm.

4.5. *tert*-Butyl-5-formyl-2,2-dimethyl-1,3-dioxan-5-ylcarbamate **13**

DMSO (4.8 mL, 67.6 mmol) was added to a solution of oxalyl chloride (4.0 mL, 45.1 mmol) in CH₂Cl₂ (110 mL) at –78 °C. The reaction mixture was stirred at room temperature for 30 min. Then, a solution of alcohol **12** (5.89 g, 22.5 mmol) in CH₂Cl₂ (32 mL) is added to the mixture. After 30 min, Et₃N (19 mL, 135.2 mmol) was added and the mixture warmed to room temperature and stirred for additional 30 min. HCl (1.0 M, 12.5 mL) was added and the solution was extracted with CH₂Cl₂. The organic layers were combined, washed with NaHCO₃ and then with brine, dried (MgSO₄). After filtration, the solvent was removed under reduced pressure. The residue was purified by chromatography on silica gel (cyclohexane/EtOAc 8:2) to give 5.63 g (97% yield) of the required product **13** as a yellow powder.

Mp 62 °C. ¹H NMR (400 MHz, CDCl₃): δ=9.55 (s, 1H), 5.62 (s, 1H), 4.00 (m, 2H), 3.85 (m, 2H), 1.40 (s, 15H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ=199.3, 155.4, 98.6, 80.8, 62.5, 59.7, 28.1, 27.1, 19.5 ppm. IR (thin film): ν=3343, 2980, 2936, 1696, 1502, 1454, 1367, 1248, 1202, 1159, 1078, 1050, 938, 829, 782, 732, 707 cm^{–1}. MS (30 eV, ES): *m/z* (%): 298 (11) [M+K]⁺, 282 (100) [M+Na]⁺, 226 (12), 153 (15), 146 (6), 102 (8). ESI-HRMS: calcd for C₁₂H₂₁NO₅ [M+Na]⁺ 282.1317; found 282.1326.

4.6. 5-(1*S**,2*S**,3*Z*)-5-{*N*-*tert*-Butyloxycarbonyl-2-[(*tert*-butyldiphenylsilyl)oxy]ethyl-4-diisopropylcarbamoyloxy-pent-3-en-1-ol}-2,2-dimethyl-1,3-dioxane (±)-**15**

TMEDA (7.6 mL, 50.4 mmol) and *n*-BuLi (1.6 M in hexanes, 31.5 mL, 50.4 mmol) were successively added to a solution of carbamate **9** (12.14 g, 25.2 mmol) in Et₂O (20 mL) at –78 °C. After 1 h stirring, were added freshly distilled Ti(Oi-Pr)₄ (22.6 mL, 75.6 mmol) (orange colouration through the transmetallation reaction) and then, a solution of aldehyde **13** (5.97 g, 22.9 mmol) in THF (85 mL). The mixture was stirred for 2 h at –78 °C, neutralized by addition of HCl (1.0 M, 230 mL) and warmed up to room temperature. The mixture was filtrated through a pad of Celite® and extracted with Et₂O. The organic layers were washed with NaHCO₃ and brine, dried (MgSO₄), filtered and the solvent removed under reduced pressure. The residue was purified by chromatography on silica gel (cyclohexane/Et₂O 8:2 to 6:4) to give 9.70 g (76% yield) of the required product (±)-**15** as a viscous colourless oil.

¹H NMR (400 MHz, CDCl₃): δ=7.68 (m, 4H), 7.40 (m, 6H), 6.12 (broad s, 1H), 5.14 (d, *J*=10.5 Hz, 1H), 5.08 (d, *J*=11.9 Hz, 1H), 4.36 (d, *J*=11.9 Hz, 1H), 4.05 (m, 3H), 3.71 (m, 4H), 2.54 (m, 1H), 1.86 (s, 3H), 1.83 (m, 2H), 1.46 (s, 9H), 1.41 (s, 3H), 1.38 (s, 3H), 1.15 (m, 12H), 1.05

(s, 9H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ=158.1, 153.8, 144.5, 135.6, 133.9, 129.5, 127.6, 116.5, 98.7, 79.8, 75.6, 64.3, 63.7, 62.4, 56.4, 46.6, 45.6, 36.5, 33.8, 28.4, 26.9, 24.2, 23.0, 21.8, 21.6, 20.6, 20.4, 20.2, 19.2 ppm. IR (thin film): ν=3319, 2967, 2932, 1674, 1623, 1473, 1428, 1369, 1294, 1256, 1228, 1203, 1154, 1110, 1087, 1044, 908, 824, 784, 730, 701 cm^{–1}. MS (30 eV, ES): *m/z* (%): 780 (9) [M+K]⁺, 764 (50) [M+Na]⁺, 520 (41), 504 (53), 323 (17), 314 (30), 282 (100), 226 (16). ESI-HRMS: calcd for C₄₁H₆₄N₂O₈Si [M+Na]⁺ 763.4330; found 763.4348.

4.7. 5-(3*R**,4*S**)-5-{*N*-*tert*-Butyloxycarbonyl-3-[(*tert*-butyldiphenylsilyl)oxy]ethyl-4-hydroxy-pyrrolidine)-2,2-dimethyl-1,3-dioxane (±)-**16**

Through a solution of vinylcarbamate (±)-**15** (2.41 g, 3.25 mmol) in CH₂Cl₂ (16 mL) at –78 °C was bubbled an ozone flow. After 30 min reaction (TLC control), the ozone was replaced by argon for 10 min. Then, Me₂S (9.7 mL, 129.9 mmol) was added and the mixture was warmed up to room temperature and stirred overnight. The mixture was extracted with CH₂Cl₂ and the organic layers were washed with H₂O, dried (Na₂SO₄), filtered and the solvent removed under reduced pressure. To a solution of the previous hemi-aminal (2.37 g, 3.25 mmol in theory) in a mixture MeOH/AcOH (1:1) (32 mL) at room temperature was added NaBH₃CN (2.15 g, 32.5 mmol). After 30 min stirring, the mixture was neutralized at 0 °C by addition of H₂O (50 mL) and NaHCO₃ (until neutral pH, 250 mL). The mixture was extracted with Et₂O and the organic layers were washed with H₂O and brine, dried (MgSO₄), filtered and the solvent removed under reduced pressure. The residue was purified by chromatography on silica gel (pentane/Et₂O 6:4) to give 921 mg (50% yield over two steps) of the required product (±)-**16** as a viscous colourless oil; ¹H & ¹³C NMR: *no data* (presence of rotamer compounds).

4.8. 5-(3*R**)-5-{*N*-*tert*-Butyloxycarbonyl-3-[(*tert*-butyldiphenylsilyl)oxy]ethyl-pyrrolidin-4-one}-2,2-dimethyl-1,3-dioxane (±)-**17**

Dess–Martin periodinane (823 mg, 1.90 mmol) was added to a solution of alcohol (±)-**16** (722 mg, 1.27 mmol) in CH₂Cl₂ (13 mL). The mixture was stirred for 1 h at room temperature and then neutralized by addition of a mixture NaHCO₃/Na₂S₂O₃ (1:1) (7.0 mL). The mixture was extracted with CH₂Cl₂ and the organic layers were washed with H₂O, dried (MgSO₄), filtered and the solvent removed under reduced pressure. The residue was purified by chromatography on silica gel (pentane/Et₂O 6:4) to give 657 mg (91% yield) of the required product (±)-**17** as a viscous colourless oil.

¹H NMR (400 MHz, CDCl₃): δ=7.66 (m, 4H), 7.42 (m, 6H), 4.04 (t, *J*=9.0 Hz, 2H), 3.76 (m, 4H), 3.53 (d, *J*=9.0 Hz, 2H), 3.17 (t, *J*=9.0 Hz, 1H), 2.85 (m, 1H), 2.19 (m, 1H), 1.54 (m, 12H), 1.49 (s, 3H), 1.07 (s, 9H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ=211.2, 153.9, 135.5, 133.3, 129.8, 127.8, 99.2, 81.0, 65.9, 62.0; 62.0, 62.0, 48.2, 41.8, 31.4, 28.5, 28.5, 28.5, 26.9, 19.1 ppm. IR (thin film): ν=2932, 2859, 1756, 1694, 1473, 1455, 1428, 1381, 1366, 1274, 1231, 1163, 1103, 997, 965, 908, 862, 824, 772, 729, 701, 687 cm^{–1}. MS (40 eV, ES): *m/z* (%): 606 (11) [M+K]⁺, 590 (100) [M+Na]⁺. ESI-HRMS: calcd for C₃₂H₄₅NO₆Si [M+Na]⁺ 590.2914; found 590.2912.

4.9. 5-(3*S**,4*R**)-5-{*N*-*tert*-Butyloxycarbonyl-3-[(*tert*-butyldiphenylsilyl)oxy]ethyl-4-hydroxy-4-methyl-pyrrolidine)-2,2-dimethyl-1,3-dioxane (±)-**19**

Method with MeLi: A solution of MeLi (1.6 M in Et₂O, 920 μL, 1.47 mmol) was added to a solution of ketone (±)-**17** (167 mg, 0.29 mmol) in THF (3.0 mL). The mixture was stirred for 4 h at

–78 °C, neutralized by addition of a 10% aqueous solution of NaHSO₄ (5.0 mL) and warmed up to room temperature. The mixture was extracted with Et₂O and the organic layers were washed with NaHCO₃ and brine, dried (MgSO₄), filtered and the solvent removed under reduced pressure. The residue was purified by chromatography on silica gel (pentane/Et₂O 7:3) to give the only non-desired diastereoisomer (±)-**19** (70 mg, 41% yield) as a viscous colourless oil.

Method with MeLi/CeCl₃: CeCl₃·7H₂O is prepared from CeCl₃·7H₂O (1.36 g, 3.59 mmol) by drying under vacuum at 140 °C for 2 h. After cooling down to room temperature, THF (6.0 mL) was added under argon atmosphere. A solution of MeLi (1.6 M in Et₂O, 4.5 mL, 7.18 mmol) was then added at –78 °C and the mixture was stirred for 1 h at –78 °C before a solution of ketone (±)-**17** (309 mg, 0.54 mmol) in THF (12 mL) was introduced to the mixture. The reaction was stirred for 2 h at –78 °C and neutralized by addition of NH₄Cl (15 mL). After warming up to room temperature, the mixture was extracted with Et₂O and the organic layers were washed with brine, dried (MgSO₄), filtered and the solvent removed under reduced pressure. The residue was purified by chromatography on silica gel (pentane/Et₂O 7:3) to give the only diastereoisomer (±)-**19** (207 mg, 65% yield) as a viscous colourless oil.

¹H NMR (400 MHz, CDCl₃): δ=7.66 (m, 4H), 7.41 (m, 6H), 4.07 (dd, *J*=12.0/4.8 Hz, 2H), 3.83 (dd, *J*=12.0/8.0 Hz, 2H), 3.72 (t, *J*=5.6 Hz, 2H), 3.55 (dd, *J*=11.2/8.8 Hz, 1H), 2.80 (dd, *J*=11.2/11.2 Hz, 1H), 2.38 (m, 1H), 2.17 (s, 6H), 1.83 (m, 1H), 1.43 (s, 10H), 1.05 (s, 9H), 1.01 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ=153.6, 135.5, 133.7, 129.6, 127.6, 98.8, 81.1, 79.8, 63.6, 61.9, 60.9, 59.5, 51.1, 43.7, 29.9, 28.7, 28.5, 26.9, 19.4, 19.1 ppm. IR (thin film): ν=3363, 2931, 2858, 1666, 1473, 1428, 1392, 1367, 1255, 1162, 1110, 1085, 1007, 939, 909, 857, 823, 734, 701, 688 cm^{–1}. MS (30 eV, ES): *m/z* (%): 583 (9) [M+H]⁺, 566 (100) [M+Na–(CH₃)₂CO]⁺, 544 (46) [M+H–(CH₃)₂CO]⁺, 488 (12), 444 (16), 214 (10). ESI-HRMS: calcd for C₃₃H₄₉NO₆Si [M–(CH₃)₂CO+Na]⁺ 566.2914; found 566.2936.

4.10. 5-(3S*,4R*)-5-{*N*-tert-Butyloxycarbonyl-3-[(*tert*-butyldiphenylsilyl)oxy]ethyl-4-hydroxy-4-methyl-pyrrolidin-2-one)-2,2-dimethyl-1,3-dioxane (±)-**20**

To a stirred solution of pyrrolidine (±)-**19** (107 mg, 0.18 mmol) in a mixture AcOEt/H₂O (2:1) (3.0 mL) were added sodium hydrogencarbonate (100 mg, 1.19 mmol) and sodium periodate (198 mg, 0.92 mmol). After 15 min of vigorous stirring, ruthenium chloride hydrate (38 mg, 0.07 mmol) was added. Following 40 h of stirring at room temperature, brine (3.0 mL) was added and the product was extracted with CH₂Cl₂. The organic layers were combined and washed with H₂O and brine, dried (MgSO₄), filtered and the solvent removed under reduced pressure. The residue was purified by chromatography on silica gel (pentane/Et₂O 6:4) to give the required product (±)-**20** (57 mg, 52% yield) as a viscous colourless oil.

¹H NMR (400 MHz, CDCl₃): δ=7.71 (m, 4H), 7.42 (m, 6H), 4.63 (d, *J*=12.3 Hz, 1H), 4.48 (d, *J*=11.6 Hz, 1H), 4.16 (dd, *J*=11.6/1.5 Hz, 1H), 4.04 (s large, 1H), 3.97 (dd, *J*=12.3/1.5 Hz, 1H), 3.95 (ddd, *J*=7.2/6.2/2.3 Hz, 2H), 2.67 (ddd, *J*=7.0/6.9/2.3 Hz, 1H), 2.01 (ddd, *J*=14.0/6.9/6.2 Hz, 1H), 1.82 (ddd, *J*=14.0/7.2/7.0 Hz, 1H), 1.59 (s, 3H), 1.56 (s, 9H), 1.44 (s, 3H), 1.26 (s, 3H), 1.08 (s, 9H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ=172.9, 150.3, 135.6, 133.7, 129.7, 127.7, 99.7, 84.1, 77.4, 62.1, 61.8, 60.6, 60.5, 48.3, 28.1, 27.7, 26.9, 26.8, 20.8, 19.7, 19.2 ppm.

4.11. 5-(3S*,4R*)-5-{*N*-tert-Butyloxycarbonyl-3-[(*p*-nitrobenzoyl)oxy]ethyl-4-hydroxy-4-methyl-pyrrolidine)-2,2-dimethyl-1,3-dioxane (±)-**21**

To a stirred solution of pyrrolidine (±)-**19** (200 mg, 0.34 mmol) in THF (4.3 mL) was added tetrabutylammonium fluoride trihydrate (162 mg, 0.51 mmol). After 30 min of stirring at room temperature,

NH₄Cl (4.0 mL) was added and the product was extracted with AcOEt. The organic layers were combined and washed with H₂O and brine, dried (MgSO₄), filtered and the solvent removed under reduced pressure.

To a stirred solution of the previous product (73 mg, 0.21 mmol) in CH₂Cl₂ (2.0 mL) were added triethylamine (95 µL, 0.67 mmol), DMAP (1.3 mg, 0.01 mmol) and a solution of 4-nitrobenzoyl chloride (59 mg, 0.32 mmol) in CH₂Cl₂ (1.0 mL). After 1 h stirring at room temperature, NH₄Cl (2.0 mL) was added and the product was extracted with CH₂Cl₂. The organic layers were combined and washed with H₂O and brine, dried (MgSO₄), filtered and the solvent removed under reduced pressure. The residue was purified by chromatography on silica gel (pentane/AcOEt 1:1) to give the required product (±)-**21** (80 mg, 61% yield over two steps) as colourless crystals.

¹H NMR (400 MHz, CDCl₃): δ=8.24 (m, 4H), 5.14 (d, *J*=12.0 Hz, 1H), 4.67 (d, *J*=12.0 Hz, 1H), 4.54 (m, 1H), 4.42 (dd, *J*=6.9/6.9 Hz, 1H), 4.35 (s large, 1H), 3.91 (d, *J*=12.0 Hz, 1H), 3.78 (d, *J*=12.0 Hz, 1H), 3.62 (m, 1H), 2.79 (dd, *J*=11.7/10.8 Hz, 1H), 2.33 (m, 1H), 2.11 (m, 1H), 1.75 (m, 1H), 1.65 (s, 3H), 1.52 (s, 3H), 1.39 (s, 9H), 1.33 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ=164.5, 150.5, 135.5, 130.6, 123.5, 119.9, 98.8, 81.0, 80.0, 65.2, 61.8, 60.8, 59.6, 50.4, 43.1, 34.1, 28.3, 26.1, 22.3, 14.0 ppm.

4.12. 5-(3S*,4S*)-5-{*N*-tert-Butyloxycarbonyl-3-[(*tert*-butyldiphenylsilyl)oxy]ethyl-4-hydroxy-4-methyl-pyrrolidine)-2,2-dimethyl-1,3-dioxane (±)-**18**

Trimethylsulfoxonium iodide (Me₃SOI) (140 mg, 0.62 mmol) was added to a solution of NaH (25 mg, 0.62 mmol) (washed two times with 0.5 mL of distilled cyclohexane) in DMSO (1.2 mL). After 30 min stirring at room temperature, neat ketone (±)-**17** (70 mg, 0.12 mmol) was added in one portion and the mixture was heated at 60 °C for 1.5 h. After cooling down, the reacting mixture was then neutralized at 0 °C by addition of H₂O (1.0 mL) and then extracted with Et₂O. The combined organic layers were washed with H₂O and brine, dried (MgSO₄), filtered and the solvent removed under reduced pressure.

To a stirred solution of the previous crude product in Et₂O (0.5 mL) at 0 °C was added a solution of LiAlH₄ (1.0 M in Et₂O, 90 µL, 0.09 mmol). The resulting mixture was allowed to warm up to room temperature and stirred over 30 min before 2-propanol (400 µL) was added at 0 °C. The resulting mixture was filtered through a pad of Celite® and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (pentane/Et₂O 1:1) to give the required diastereoisomer (±)-**18** (37 mg, 52% yield over two steps) as a viscous colourless oil.

¹H NMR (400 MHz, CDCl₃): δ=7.65 (m, 4H), 7.41 (m, 6H), 4.11 (d, *J*=12.8 Hz, 1H), 3.94 (d, *J*=12.8 Hz, 1H), 3.85 (d, *J*=12.0 Hz, 1H), 3.72 (m, 1H), 3.65 (m, 1H), 3.49 (m, 1H), 3.44 (d, *J*=12.0 Hz, 1H), 3.09 (t, *J*=11.2 Hz, 1H), 2.17 (s, 6H), 2.10 (m, 1H), 1.72 (m, 1H), 1.57 (m, 1H), 1.45 (s, 9H), 1.33 (s, 3H), 1.05 (s, 9H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ=156.2, 135.5, 133.4, 129.8, 127.7, 98.0, 82.4, 80.6, 63.5, 63.4, 62.9, 62.5, 51.1, 41.9, 30.9, 29.2, 28.5, 27.9, 20.5, 19.1 ppm. IR (thin film): ν=3403, 3071, 2931, 2858, 1664, 1473, 1428, 1403, 1367, 1256, 1169, 1111, 1006, 911, 858, 823, 775, 737, 702 cm^{–1}. MS (30 eV, ES): *m/z* (%): 606 (15) [M+Na]⁺, 583 (5) [M+H]⁺, 566 (100) [M+Na–(CH₃)₂CO]⁺, 544 (12) [M+H–(CH₃)₂CO]⁺, 488 (8), 444 (12), 236 (5), 219 (11), 214 (15). ESI-HRMS: calcd for C₃₃H₄₉NO₆Si [M–(CH₃)₂CO+Na]⁺ 566.2914; found 566.2924.

Acknowledgements

J.B. thanks ANR for a post-doctoral fellowship. We thank Elise Prost for assistance with NMR experiments

This work was partly supported by grants from the Swedish Research Council (Grants 621-2009-4736 and 622-2009-371). S.S. thanks the Wenner-Gren Foundations for a postdoctoral fellowship. Computer time was generously provided by the PDC Center for High Performance Computing.

Supplementary data

Supplementary data associated with this article can be found, in the online version,

References and notes

- For the isolation and biology of salinosporamide A, see: (a) Feling, R. H.; Buchanan, G. O.; Mincer, T. J.; Kauffman, C. A.; Jensen, P. R.; Fenical, W. *Angew. Chem.* **2003**, *115*, 369–371; *Angew. Chem., Int. Ed.* **2003**, *42*, 355–357; (b) Chauhan, D.; Catley, L.; Li, G.; Podar, K.; Hideshima, T.; Velankar, M.; Mitsiades, C.; Mitsiades, N.; Yasui, H.; Letai, A.; Ova, H.; Berkers, C.; Nicholson, B.; Chao, T.-H.; Neuteboom, S. T. C.; Richardson, P.; Palladino, M. A.; Anderson, K. C. *Cancer Cell* **2005**, *8*, 407–419; (c) Groll, M.; Huber, R.; Potts, B. C. M. *J. Am. Chem. Soc.* **2006**, *128*, 5136–5141; (d) Beer, L. L.; Moore, B. S. *Org. Lett.* **2007**, *9*, 845–848; (e) Fenical, W.; Jensen, P. R.; Palladino, M. A.; Lam, K. S.; Lloyd, G. K.; Potts, B. C. *Bioorg. Med. Chem.* **2009**, *17*, 2175–2180; (f) Obaidat, A.; Weiss, J.; Wahlgren, B.; Manam, R. R.; Macherla, V. R.; McArthur, K.; Chao, T.-H.; Palladino, M. A.; Lloyd, G. K.; Potts, B. C.; Enna, S. J.; Neuteboom, S. T. C.; Hagenbuch, B. *J. Pharmacol. Exp. Ther.* **2011**, *337*, 479–486.
- Salinosporamide syntheses: for reviews see: (a) Gulder, T. A.; Moore, B. S. *Angew. Chem., Int. Ed.* **2010**, *49*, 9346–9367; (b) Potts, B. C.; Lam, K. S. *Mar. Drugs* **2010**, *8*, 835–880; (c) Shibasaki, M.; Kanai, M.; Fukuda, N. *Chem.—Asian J.* **2007**, *2*, 20–38.
- Enantioselective salinosporamide syntheses: (a) Reddy, L. R.; Saranavan, P.; Corey, E. J. *J. Am. Chem. Soc.* **2004**, *126*, 6230–6231; (b) Endo, A.; Danishefsky, S. J. *J. Am. Chem. Soc.* **2005**, *127*, 8298–8299; (c) Reddy, L. R.; Fournier, J.-F.; Reddy, B. V. S.; Corey, E. J. *Org. Lett.* **2005**, *7*, 2699–2701; (d) Ling, T.; Macherla, V. R.; Manam, R. R.; McArthur, K. A.; Potts, B. C. M. *Org. Lett.* **2007**, *9*, 2289–2292; (e) Takahashi, K.; Midori, M.; Kawano, K.; Ishihara, J.; Hatakeyama, S. *Angew. Chem.* **2008**, *120*, 6340–6342; *Angew. Chem., Int. Ed.* **2008**, *47*, 6244–6246; (f) Fukuda, T.; Sugiyama, K.; Arima, S.; Harigaya, Y.; Nagamitsu, T.; Omura, S. *Org. Lett.* **2008**, *10*, 4239–4242; (g) Nguyen, H.; Ma, G.; Romo, D. *Chem. Commun.* **2010**, 4803–4805; (h) Sato, H.; Fukuda, H.; Tomizawa, M.; Masaki, T.; Shibuya, M.; Kanoh, N.; Iwabuchi, Y. *Heterocycles* **2010**, *81*, 2239–2246; (i) Nguyen, H.; Ma, G.; Gladysheva, T.; Fremgen, T.; Romo, D. *J. Org. Chem.* **2011**, *76*, 2–12; (j) Kaiya, Y.; Hasegawa, J.; Mormose, T.; Sato, T.; Chida, N. *Chem.—Asian J.* **2011**, *6*, 209–219; (k) Satoh, N.; Yotoshima, S.; Fukuyama, T. *Org. Lett.* **2011**, *13*, 3028–3031 For racemic syntheses, see: (l) Mulholland, N. P.; Pattenden, G.; Walters, I. A. S. *Org. Biomol. Chem.* **2006**, *4*, 2845–2846; (m) Mulholland, N. P.; Pattenden, G.; Walters, I. A. S. *Org. Biomol. Chem.* **2008**, *6*, 2782–2789; (n) Ma, G.; Nguyen, H.; Romo, D. *Org. Lett.* **2007**, *9*, 2143–2146.
- Formal salinosporamide syntheses: (a) Caubert, V.; Massé, J.; Retailleau, P.; Langlois, N. *Tetrahedron Lett.* **2007**, *48*, 381–384; (b) Margalef, I. V.; Rupnicki, L.; Lam, H. W. *Tetrahedron* **2008**, *64*, 7896–7901; (c) Mormose, T.; Kaiya, Y.; Hama, N.; Hasegawa, J.; Sato, T.; Chida, N. *Synthesis* **2009**, 2983–2991; (d) Mosey, R. A.; Tepe, J. J. *Tetrahedron Lett.* **2009**, *50*, 295–297; (e) Struble, J. R.; Bode, J. W. *Tetrahedron* **2009**, *65*, 4957–4967; (f) Ling, T.; Potts, B. C.; Macherla, V. R. *J. Org. Chem.* **2010**, *75*, 3882–3885.
- With the exception of Chida synthesis, which employed a D-arabinose derivative as starting material in Refs. 3j,4c.
- Hoppe allylation: For a recent review see: (a) Hoppe, D. *Synthesis* **2009**, 43–55 For crotyltitanation of aldehydes from primary crotylcarbamates see: (b) Hoppe, D. *Angew. Chem.* **1984**, *96*, 930–946; *Angew. Chem., Int. Ed. Engl.* **1984**, *23*, 932–948; (c) Hoppe, D.; Zschage, O. *Angew. Chem.* **1989**, *101*, 67–69; *Angew. Chem., Int. Ed. Engl.* **1989**, *28*, 69–71; (d) Hoppe, D.; Zschage, O. *Tetrahedron* **1992**, *48*, 8389–8392; Hoppe, D.; Hense, T. *Angew. Chem.* **1997**, *109*, 2376–2410; *Angew. Chem., Int. Ed.* **1997**, *36*, 2282–2316; (e) Fargeas, V.; Le Ménez, P.; Berque, I.; Ardisson, J.; Pancrazi, A. *Tetrahedron* **1996**, *52*, 6613–6634; (f) Berque, I.; Le Ménez, P.; Razon, P.; Anies, C.; Pancrazi, A.; Ardisson, J.; Neuman, A.; Prangé, T.; Brion, J.-D. *Synlett* **1998**, 1132–1134; (g) Berque, I.; Le Ménez, P.; Razon, P.; Pancrazi, A.; Ardisson, J.; Brion, J.-D. *Synlett* **1998**, 1135–1137; (h) Berque, I.; Le Ménez, P.; Razon, P.; Mahuteau, J.; Férézou, J.-P.; Pancrazi, A.; Ardisson, J.; Brion, J.-D. *J. Org. Chem.* **1999**, *64*, 373–381; (i) De Lemos, E.; Porée, F. H.; Commerçon, A.; Betzer, J.-F.; Pancrazi, A.; Ardisson, J. *Angew. Chem.* **2007**, *48*, 9509–9600; *Angew. Chem., Int. Ed.* **2007**, *46*, 1917–1921; (j) De Lemos, E.; Porée, F. H.; Bourin, A.; Barbion, J.; Agouridas, E.; Lannou, M.-L.; Commerçon, A.; Betzer, J.-F.; Pancrazi, A.; Ardisson, J. *Chem.—Eur. J.* **2008**, *14*, 11092–11112; (k) De Lemos, E.; Agouridas, E.; Sorin, G.; Guerreiro, A.; Commerçon, A.; Pancrazi, A.; Betzer, J.-F.; Lannou, M.-L.; Ardisson, J. *Chem.—Eur. J.* **2011**, *17*, 10123–10134.
- Hoppe allylation: for crotyltitanation of aldehydes from racemic secondary crotylcarbamates see: (a) Zschage, O.; Schwark, J. R.; Hoppe, D. *Angew. Chem.* **1990**, *29*, 336–337; *Angew. Chem., Int. Ed. Engl.* **1990**, *29*, 296–298; (b) Zschage, O.; Schwark, J. R.; Krämer, T.; Hoppe, D. *Tetrahedron* **1992**, *48*, 8377–8388 For crotyltitanation of aldehydes from optically active secondary crotylcarbamates see: (c) Hoppe, D.; Krämer, T. *Angew. Chem.* **1986**, *29*, 171–173; *Angew. Chem., Int. Ed. Engl.* **1986**, *25*, 160–162; (d) Krämer, T.; Hoppe, D. *Tetrahedron Lett.* **1987**, *28*, 5149–5152; (e) Krämer, T.; Scharwark, J.-R.; Hoppe, D. *Tetrahedron Lett.* **1989**, *30*, 7037–7040; (f) Schwark, J. R.; Hoppe, D. *Synthesis* **1990**, 291–294; (g) See Ref. 6d. For allyltitanation of aldehydes from optically active aliphatic secondary allylcarbamates see: (h) Razon, P.; Dhulut, S.; Bezenine-Lafollée, S.; Courtieu, J.; Pancrazi, A.; Ardisson, J. *Synthesis* **2005**, 102–108; (i) Razon, P.; N'Zoutani, M.-A.; Dhulut, S.; Bezenine-Lafollée, S.; Courtieu, J.; Pancrazi, A.; Ardisson, J. *Synthesis* **2005**, 109–121 For allyltitanation of aldehydes from optically active cyclic secondary allylcarbamates see: (j) Becker, J.; Grimme, S.; Frölich, R.; Hoppe, D. *Angew. Chem.* **2007**, *119*, 1672–1676; *Angew. Chem., Int. Ed.* **2007**, *46*, 1645–1649; (k) Becker, J.; Frölich, R.; Kataeva, O.; Hoppe, D. *Eur. J. Org. Chem.* **2007**, 3349–3364; (l) Becker, J.; Bergander, K.; Frölich, R.; Hoppe, D. *Angew. Chem.* **2008**, *120*, 1678–1681; *Angew. Chem., Int. Ed.* **2008**, *47*, 1654–1657; (m) Hémy, T.; Becker, J.; Frölich, R.; Hoppe, D. *Eur. J. Org. Chem.* **2010**, 3711–3720; (n) Hémy, T.; Wibbeling, B.; Frölich, R.; Hoppe, D. *Synthesis* **2010**, 329–342; (o) Duhlut, S.; Bourin, A.; Lannou, M.-L.; Fleury, E.; Lensen, N.; Chelain, E.; Pancrazi, A.; Ardisson, J.; Fahy, J. *Eur. J. Org. Chem.* **2007**, 5235–5243.
- Ooi, H.; Ishibashi, N.; Iwabuchi, Y.; Ishihara, J.; Hatakeyama, S. *J. Org. Chem.* **2004**, *69*, 7765–7768.
- Earlier investigations relied on the simultaneous control of C2 and C3 centres through allylation reaction of the corresponding bulky methylketone with allylcarbamate ($\pm$)-**11**, under Hoppe conditions, have been conducted to provide directly the desired racemic homoallylic alcohol. Unfortunately, despite several attempts, no reaction occurred; the starting material was recovered along with degradation products. The methylketone was smoothly obtained from aldehyde **13** by methylation and subsequent Swern oxidation.

Methylation of pyrrolidin-3-ones (salinosporamide numbering): Mono-substituted at C2, C1 or C4: (a) De Weerd, P. (Novartis AG, CH-4002 Basel, CH) WO/2006/066896, PTC/EP2005/013786; (b) Davis, F. A.; Ramachandrar, T.; Liu, H. *Org. Lett.* **2004**, *6*, 3393–3395; (c) Del Valle, J. R.; Goodman, M. *Angew. Chem., Int. Ed.* **2002**, *41*, 1600–16002; (d) Haddad, M.; Larchevêque, M. *Tetrahedron: Asymmetry* **2005**, *16*, 2243–2247; (e) Krapcho, J.; Turk, C.; Cushman, D. W.; Powell, J. R.; DeForrest, J. M.; Spitzmiller, E. R.; Karanewsky, D. S.; Duggan, M.; Rovnvak, G.; Scharwark, J.; Natarajan, S.; Godfrey, J. D.; Ryono, D. E.; Neubeck, R.; Atwa, K. S.; Petrillo, E. W., Jr. *J. Med. Chem.* **1988**, *31*, 1148–1160; (f) Ma, Z.; Hu, H.; Xiong, W.; Zhai, H. *Tetrahedron* **2007**, *63*, 7523–7531; (g) Chang, M.-Y.; Pai, C.-L.; Chen, H.-P. *Tetrahedron Lett.* **2005**, *46*, 7705–7709 Polysubstituted: (h) Baldwin, J. E.; Bamford, S. J.; Fryer, A. M. *Tetrahedron* **1997**, *53*, 5233–5254; (i) Ma, D.; Wu, W.; Deng, P. *Tetrahedron Lett.* **2001**, *42*, 6929–6931; (j) Gupta, S.; Schafmeister, C. E. *J. Org. Chem.* **2009**, *74*, 3652–3658; (k) Blanco, M.-J.; Sardina, F. J. *J. Org. Chem.* **1998**, *63*, 3411–3434; (l) Davis, F. A.; Xu, H.; Wu, Y.; Zhang, J. *Org. Lett.* **2006**, *8*, 2273–2276 Chelate formation: (m) Molonay, M. G.; Yaqoob, M. *Synlett* **2004**, 1631–1633; (n) Ooi, T.; Miki, T.; Maruoka, K. *Org. Lett.* **2005**, *7*, 191–193; (o) Moreau, R. J.; Sorensen, E. J. *Tetrahedron* **2007**, *63*, 6446–6453; (p) Donohoe, T. J.; Chiu, J. Y. K.; Thomas, R. E. *Org. Lett.* **2007**, *9*, 421–424.
- The structure was built using Sybyl-X (Tripos, Inc., St. Louis, Missouri, USA), then optimized by energy minimization in the Tripos force field. Conformational sampling was performed using Omega2 (Open Eye Scientific software, Inc., Santa Fe, New Mexico, USA) to generate 200 low energy conformers.
- Applications of CeCl₃: (a) Bartoli, G.; Marcantoni, E.; Marcolini, M.; Sambri, L. *Chem. Rev.* **2010**, *110*, 6104–6143; (b) Imamoto, T.; Takiyama, N.; Nakamura, K.; Hatajima, T.; Kamiya, Y. *J. Am. Chem. Soc.* **1989**, *111*, 4392–4398 Catalytic synthesis of tertiary alcohol from ketones with organometallic reagents: (c) Hatanoto, M.; Ishihara, K. *Synthesis* **2008**, 1647–1675 Enantioselective catalytic formation of quaternary stereogenic centers: (d) Cozzi, P. G.; Hilgraf, R.; Zimmermann, N. *Eur. J. Org. Chem.* **2007**, 5969–5994.
- (a) Mohapatra, D. K.; Mondal, D.; Gonnade, R. G.; Chorghade, M. S.; Gurjar, M. K. *Tetrahedron Lett.* **2006**, *47*, 6031–6035; (b) Han, J.-S.; Lowary, T. L. *J. Org. Chem.* **2003**, *68*, 4116–4119.
- To overcome this unfavourable diastereoselectivity, different methylation conditions of ketones without spiroketal moiety were screened without any satisfactory result.

16. Attempts to oxidize the lactam resulting from (±)-16 were unsuccessful leading mainly to the decomposition of the starting material. Therefore, the methylation of the expected ketone could not be studied.

15. The methylation of a corresponding linear ketone provided a mixture of two diastereomers. The required alcohol was obtained in a rather low 20% yield, the main isolated product being the unwanted diastereomer.

17. Stereoselective facial addition of the methyl group in presence of dimethylzinc and optically active ligands was studied on pyrrolidinone (±)-17 and linear ketone corresponding to (±)-15 (cf. Ref. 15) under various conditions (Me₂Zn with additives: prolinol, ephedrine, TADDOL) Ref. 12c,d; however, all attempts were ineffective: no reaction occurred, the starting material was recovered along with degradation products.
18. Corey, E. J.; Chaykovsky, M. J. *Am. Chem. Soc.* **1965**, 87, 1353–1364.
19. (a) Lee, C.; Yang, W.; Parr, R. G. *Phys. Rev. B: Condens. Matter* **1988**, 37, 785–789; (b) Becke, A. D. *Phys. Rev. A: At., Mol., Opt. Phys.* **1988**, 38, 3098–3100; (c) Becke, A. D. *J. Chem. Phys.* **1992**, 96, 2155–2160; (d) Becke, A. D. *J. Chem. Phys.* **1992**, 97, 9173–9177; (e) Becke, A. D. *J. Chem. Phys.* **1993**, 98, 5648–5652.
20. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, J. A., Jr.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. *Gaussian 03, Revision D.01*; Gaussian: Wallingford, CT, 2004.
21. (a) Barone, V.; Cossi, M. J. *Phys. Chem. A* **1998**, 102, 1995–2001; (b) Cossi, M.; Rega, N.; Scalmani, G.; Barone, V. *J. Comput. Chem.* **2003**, 24, 669–681.